Custom autologous cell therapies face immense manufacturing bottlenecks, steep financial costs, and vein-to-vein logistical ...

MHRA's first two centralised programmes are focusing on software or AI used as a medical device (SaMD/AIaMD) and the use of ...

The US Advanced Research Projects Agency for Health (ARPA-H) has awarded $125 million in funding, split across five groups, ...

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...

AstraZeneca and Daiichi Sankyo's Enhertu, given in combination with Roche's Perjeta, has become the first new frontline ...

Roche is paying $75 million for a trispecific antibody developed by a subsidiary of China's Simcere Pharma as a treatment for ...

Novartis has paused eight clinical trials of its experimental CAR-T therapy rapcabtagene autoleucel (rap-cel or YTB323) after ...

GSK is planning to start a phase 3 trial of the new vaccine later this month, saying it will be the first late-stage trial of ...

Nine mid-sized pharma companies have signed up for the Trump administration's Most Favoured Nation (MFN) pricing deals, ...

That’s roughly how long I have to review a patient’s history, examine her, explain my diagnosis, write a prescription, and – particularly if I’m prescribing a specialty medication – walk her through ...

Takeda and Protagonist Therapeutics' hepcidin mimetic rusfertide has been approved by the FDA to treat polycythaemia vera (PV ...

An oral relaxin agonist developed by AstraZeneca, codenamed AZD5462, has been shown to improve cardiac function in patients ...